How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,409 results for

Sentinel Node Breast Biopsy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Positive non-sentinel axillary lymph nodes in breast cancer with 1-2 sentinel lymph node metastases. (Full text)

Positive non-sentinel axillary lymph nodes in breast cancer with 1-2 sentinel lymph node metastases. Recent clinical trials have shown that sentinel lymph node biopsy (SLNB) alone without axillary lymph node dissection (ALND) can offer excellent regional control if there is sentinel lymph nodes (SLN) metastases to 1-2 nodes. This study aimed to explore the predictive factors for non-sentinel lymph node (NSLN) metastasis in breast cancer patients with 1-2 positive SLNs.Patients with breast (...) (area under the receiver operating characteristic [ROC] curve [AUC] 0.712, CI: 0.614-0.811) was useful for dividing patients with positive SLN (1-2 nodes) into non-SLN-positive and non-SLN-negative groups.For 1-2 positive SLNs of breast cancer, LVI, large invasive tumor size, and HER2 over-expression are independent factors affecting NSLN metastases.

2018 Medicine

62. Regional Recurrence Risk Following a Negative Sentinel Node Procedure Does Not Approximate the False-Negative Rate of the Sentinel Node Procedure in Breast Cancer Patients Not Receiving Radiotherapy or Systemic Treatment. (PubMed)

Regional Recurrence Risk Following a Negative Sentinel Node Procedure Does Not Approximate the False-Negative Rate of the Sentinel Node Procedure in Breast Cancer Patients Not Receiving Radiotherapy or Systemic Treatment. Although the false-negative rate of the sentinel lymph node biopsy (SLNB) in breast cancer patients is 5-7%, reported regional recurrence (RR) rates after negative SLNB are much lower. Adjuvant treatment modalities probably contribute to this discrepancy. This study assessed (...) the 5-year RR risk after a negative SLNB in the subset of patients who underwent breast amputation without radiotherapy or any adjuvant treatment.All patients operated for primary unilateral invasive breast cancer between 2005 and 2008 were identified in the Netherlands Cancer Registry. Patients with a negative SLNB who underwent breast amputation and who were not treated with axillary lymph node dissection, radiotherapy, or any adjuvant systemic treatment were selected. The cumulative 5-year RR

2018 Annals of Surgical Oncology

63. The role of sentinel lymph node biopsy in the treatment of women with early stage vulval cancer: A summary of the evidence

The role of sentinel lymph node biopsy in the treatment of women with early stage vulval cancer: A summary of the evidence The role of sentinel lymph node biopsy in the treatment of women with early vulval cancer: A summary of the evidence Early-stage cancer of the vulva The International Federation of Gynaecology and Obstetrics (FIGO) categorises cancer of the vulva into stages, with early-stage (1A or 1B) defined as being confined to the vulva or perineum, with stromal invasion, and negative (...) , depending on tumour factors. Complete inguino-femoral lymph node dissection (IFLND) is associated with a high frequency of early and late complications, specifically wound infection, wound breakdown, lymphocyst and lymphoedema of the leg. 3 Sentinel lymph node biopsy (SLNB) is a procedure used to identify the first lymph node(s) to which a carcinoma drains. 4, 5 Identifying sentinel lymph nodes (SLN) allows for the resection of limited nodal tissue without removal of the entire lymph node chain

2015 Cancer Australia

64. SentiMag® and Sienna+® system for sentinel lymph node biopsy in breast cancer

SentiMag® and Sienna+® system for sentinel lymph node biopsy in breast cancer SentiMag® and Sienna+® system for sentinel lymph node biopsy in breast cancer SentiMag® and Sienna+® system for sentinel lymph node biopsy in breast cancer NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. SentiMag® and Sienna+® system (...) for sentinel lymph node biopsy in breast cancer. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms; Magnetics; Sentinel Lymph Node Biopsy; Surgical Equipments Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology

2012 Health Technology Assessment (HTA) Database.

65. [Sentinel lymph node biopsy in breast cancer treatment: indications and contraindications]

[Sentinel lymph node biopsy in breast cancer treatment: indications and contraindications] La biopsie des ganglions sentinelles dans le cadre du traitement du cancer du sein : indications et contre-indications [Sentinel lymph node biopsy in breast cancer treatment: indications and contraindications] La biopsie des ganglions sentinelles dans le cadre du traitement du cancer du sein : indications et contre-indications [Sentinel lymph node biopsy in breast cancer treatment: indications (...) biopsy in breast cancer treatment: indications and contraindications] Montreal: L'Institut national d'excellence en sante et en services sociaux (INESSS). Volume 8(3). 2012 Final publication URL Additional data URL Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasmss; Sentinel Lymph Node Biopsy Language Published French Country of organisation Canada Province or state Quebec English summary An English language summary is available. Address for correspondence L'Institut national

2012 Health Technology Assessment (HTA) Database.

66. [Sentinel lymph node biopsy in breast cancer treatment: efficacy and safety]

[Sentinel lymph node biopsy in breast cancer treatment: efficacy and safety] La biopsie des ganglions sentinelles dans le cadre du traitement du cancer du sein : efficacité et innocuité [Sentinel lymph node biopsy in breast cancer treatment: efficacy and safety] La biopsie des ganglions sentinelles dans le cadre du traitement du cancer du sein : efficacité et innocuité [Sentinel lymph node biopsy in breast cancer treatment: efficacy and safety] L'Institut national d'excellence en sante et en (...) services sociaux (INESSS) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation L'Institut national d'excellence en sante et en services sociaux (INESSS). La biopsie des ganglions sentinelles dans le cadre du traitement du cancer du sein : efficacité et innocuité. [Sentinel lymph node biopsy in breast cancer treatment: efficacy and safety] Montreal

2012 Health Technology Assessment (HTA) Database.

67. The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: A systematic review and meta-analysis. (PubMed)

The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: A systematic review and meta-analysis. To provide a systematic review and meta-analysis of studies investigating sentinel lymph node biopsy after neoadjuvant systemic therapy in pathologically confirmed node positive breast cancer patients.Pubmed and Embase databases were searched until June 19th, 2015. All abstracts were read and data (...) in every clinically node positive breast cancer patients with a negative sentinel lymph node biopsy after neoadjuvant systemic therapy.Copyright © 2015 Elsevier Ltd. All rights reserved.

2015 European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

68. Sentinel Lymph Node Metastasis in Invasive Lobular Carcinoma of the Breast (Full text)

Sentinel Lymph Node Metastasis in Invasive Lobular Carcinoma of the Breast Invasive lobular carcinoma (ILC) of the breast makes up 5 to 15 percent of all invasive breast cancers. It has distinctive clinical and histopathological features when compared to invasive ductal carcinoma (IDC). This study intends to describe factors influencing sentinel lymph node (SLN) positivity in patients with "pure" ILC.Data of 105 patients, who were treated at a tertiary oncology center, with lobular carcinoma (...) of the breast that were subjected to SLN biopsy was probed retrospectively. Patients were categorized as ≤60 and >60 years of age, positive or negative for estrogen receptor and progesterone, tumor grade I, II and III, Ki67≤15% and >30%, lymphovascular invasion presence and the presence of multicentricity and multifocality.Mean age at the time of diagnosis was 52 (38-81). Mean tumor size was 2.7 cm (0.7-13cm). Univariate analyses revealed a significant relationship between tumor size (≤2 cm vs >2cm

2018 European journal of breast health

69. Comparative Study between Sentinel Lymph Node Biopsy and Axillary Dissection in Patients with One or Two Lymph Node Metastases (Full text)

Comparative Study between Sentinel Lymph Node Biopsy and Axillary Dissection in Patients with One or Two Lymph Node Metastases Sentinel lymph node biopsy (SLNB) is a standard axillary surgery in early breast cancer. If the SLNB result is positive, subsequent axillary lymph node dissection (ALND) is a routine procedure. In 2011, the American College of Surgeons Oncology Group Z0011 trial revealed that ALND may not be necessary in early breast cancer with one or two positive sentinel lymph nodes (...) . The purpose of this study was to compare outcomes among Korean patients with one or two positive axillary lymph nodes in the final pathology who did and did not undergo ALND.A total of 131,717 patients from the Korea Breast Cancer Society registry database received breast cancer surgery from January 1995 to December 2014. Inclusion criteria were T stage 1 or 2, one or two positive lymph nodes, and having received breast-conserving surgery (BCS), whole breast radiation therapy, and no neoadjuvant therapy

2018 Journal of breast cancer

70. Improved False-Negative Rates with Intraoperative Identification of Clipped Nodes in Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy. (PubMed)

Improved False-Negative Rates with Intraoperative Identification of Clipped Nodes in Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy. Identification and resection of a clipped node was shown to decrease the false-negative rate (FNR) of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) for patients presenting with initially node-positive breast cancer.Between March 2014 and March 2016, a prospective trial analyzed 98 patients with axilla (...) -positive locally advanced breast cancer (T1-4, N1-3) to assess the feasibility and efficacy of placing clips into most suspicious biopsy-proven node. The study considered blue, radioisotope active, and suspiciously palpable nodes as sentinel lymph nodes (SLNs).The SLN identification rate was 87.8%. The median age of the patients with an SLNB (n = 86) was 44 years (range 28-66 years). Of these patients, 77 (88.4%) had cT1-3 disease, and 10 (11.6%) had cT4 disease. The majority of the patients (n = 66

2018 Annals of Surgical Oncology

71. Predictors of nonsentinel lymph node metastasis in patients with breast cancer with metastasis in the sentinel node. (Full text)

Predictors of nonsentinel lymph node metastasis in patients with breast cancer with metastasis in the sentinel node. To predict the factors related to axillary nonsentinel lymph node (NSLN) metastasis in patients with positive sentinel lymph node (SLN) of early breast cancer.The retrospective data are collected from the patients with positive SLN who received further completion axillary lymph node dissection (cALND) in Peking Union Medical Hospital between March 2016 and December 2017 (...) correlated with NSLN involvement: tumor size (X = 10.384, P = .001), SLN metastasis ratio (number of positive SLNs/number of SLNs removed × 100%) (X = 10.365, P = .001) and the number of negative sentinel nodes (X = 10.384, P = .006). In multivariate analysis and logistic regression, tumor size (odds ratio [OR] = 3.392, 95% confidence interval [CI]: 1.409-8.166, P = .006) and SLN metastasis ratio (OR = 3.514, 95% CI: 1.416-8.72, P = .007) were the independent risk factors. While the number of negative

2019 Medicine

72. Excision of both pretreatment marked positive nodes and sentinel nodes improves axillary staging after neoadjuvant systemic therapy in breast cancer. (Full text)

Excision of both pretreatment marked positive nodes and sentinel nodes improves axillary staging after neoadjuvant systemic therapy in breast cancer. Marking the axilla with radioactive iodine seed and sentinel lymph node (SLN) biopsy have been proposed for axillary staging after neoadjuvant systemic therapy in clinically node-positive breast cancer. This study evaluated the identification rate and detection of residual disease with combined excision of pretreatment-positive marked lymph nodes (...) (MLNs) together with SLNs.This was a multicentre retrospective analysis of patients with clinically node-positive breast cancer undergoing neoadjuvant systemic therapy and the combination procedure (with or without axillary lymph node dissection). The identification rate and detection of axillary residual disease were calculated for the combination procedure, and for MLNs and SLNs separately.At least one MLN and/or SLN(s) were identified by the combination procedure in 138 of 139 patients

2019 British Journal of Surgery

73. EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma ? SNMMI Endorsement

EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma ? SNMMI Endorsement GUIDELINES EANMpracticeguidelinesforlymphoscintigraphyandsentinel lymphnodebiopsyinmelanoma ChristinaBluemel 1 &KenHerrmann 1 &FrancescoGiammarile 2 &OmgoE.Nieweg 3 & JulienDubreuil 2 &AlessandroTestori 4 & RiccardoA.Audisio 5 &OdysseasZoras 6 & MichaelLassmann 1 &AnnetteH.Chakera 3 &RogerUren 7,8 &SotiriosChondrogiannis 9 & PatrickM.Colletti 10 &DomenicoRubello 9 Received:2July2015 (...) /Accepted:7July2015/Published online:25 July 2015 # Springer-VerlagBerlinHeidelberg2015 Abstract Purpose Sentinel lymph node biopsy is an essential staging tool in patients with clinically localized melanoma. The har- vestingofa sentinellymph nodeentailsa sequenceofproce- dures with participation of specialists in nuclear medicine, radiology, surgery and pathology. The aim of this document is to provide guidelines for nuclear medicine physicians performing lymphoscintigraphy for sentinel lymph node de

2015 Society of Nuclear Medicine and Molecular Imaging

74. Systematic versus sentinel-lymph-node-driven axillary-lymph-node dissection in clinically node-negative patients with operable breast cancer. Results of the GF-GS01 randomized trial (Full text)

Systematic versus sentinel-lymph-node-driven axillary-lymph-node dissection in clinically node-negative patients with operable breast cancer. Results of the GF-GS01 randomized trial Sentinel-lymph-node (SLN) resection seems to minimize systematic axillary-lymph-node dissection (sALND) side effects in operated breast cancer patients. We explored whether SLN resection achieves similar therapeutic outcomes as sALND but with fewer side effects.A randomized, controlled, open-label trial (...) with parallel-group design compared sALND restricted to cases with positive SLN biopsy (test arm, n = 774) versus SLN biopsy followed by sALND (control arm, n = 770).The five-year overall survivals in control and test arms were 96.42 and 95.64% (P = 0.2925). The estimated difference was nearly zero (precisely, - 0.79%, one-tailed 95% confidence interval (CI) limit - 2.44%). In a multivariate Cox model, the adjusted hazard ratio in the test arm was HR 0.81 (upper 95% CI limit 1.17). Advanced age (HR 1.05 per

2018 Breast cancer research and treatment Controlled trial quality: predicted high

75. Clinical utility of the additional use of blue dye for indocyanine green for sentinel node biopsy in breast cancer. (PubMed)

Clinical utility of the additional use of blue dye for indocyanine green for sentinel node biopsy in breast cancer. Indocyanine green (ICG) is widely used as a tracer in sentinel lymph node biopsy (SLNB) of patients with breast cancer. Whether SLNB performance can be improved by supplementing ICG with methylene blue dye remains controversial. This study compared the performance of SLNB when ICG was used alone or with blue dye.Consecutive patients with T1-3 primary breast cancer at our hospital (...) were recruited into our study and randomized to undergo SLNB with ICG alone (n = 62) or with the combination of ICG and blue dye (n = 65). We compared the two methods in terms of identification rate, number and detection time of sentinel lymph nodes (SLNs) removed.SLN identification rate were similar in the absence (95.2%) or presence of blue dye (98.5%, P = 0.578) but significantly, more average nodes were removed when blue dye was used (3.8 ± 1.5 versus 2.7 ± 1.2, P = 0.000), and the average time

2017 The Journal of surgical research Controlled trial quality: uncertain

76. The predictive value of methylene blue dye as a single technique in breast cancer sentinel node biopsy: a study from Dharmais Cancer Hospital (Full text)

The predictive value of methylene blue dye as a single technique in breast cancer sentinel node biopsy: a study from Dharmais Cancer Hospital Axillary lymph node dissection (ALND) has been the standard treatment of breast cancer axillary staging in Indonesia. The limited facilities of radioisotope tracer and isosulfan or patent blue dye (PBD) have been the major obstacles to perform sentinel node biopsy (SNB) in our country. We studied the application of 1% methylene blue dye (MBD) alone (...) for SNB to overcome the problem.This prospective study enrolled 108 patients with suspicious malignant lesions or breast cancer stages I-III. SNB was performed using 2-5 cc of 1% MBD and proceeded with ALND. The histopathology results of sentinel nodes (SNs) were compared with axillary lymph nodes (ALNs) for diagnostic value assessments.There were 96 patients with invasive carcinoma from July 2012 to September 2014 who were included in the final analysis. The median age was 50 (25-69) years

2017 World journal of surgical oncology

77. Swedish prospective multicenter trial on the accuracy and clinical relevance of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer (Full text)

Swedish prospective multicenter trial on the accuracy and clinical relevance of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer The timing of sentinel lymph node biopsy (SLNB) in the context of neoadjuvant systemic therapy (NAST) in breast cancer is still controversial. SLNB before NAST has been evaluated in few single-institution studies in which axillary lymph node dissection (ALND), however, was commonly not performed in case of a negative SLNB. We (...) investigated the potential clinical relevance of SLNB before NAST by performing ALND in all patients after NAST.This national multicenter trial prospectively enrolled clinically node-negative breast cancer patients planned for NAST at 13 recruiting Swedish hospitals between October 2010 and December 2015. SLNB before NAST was followed by ALND after NAST in all individuals. Repeat SLNB after NAST was encouraged but not mandatory.SLNB before NAST was performed in 224 patients. The identification rate was 100

2017 Breast cancer research and treatment

78. Intraoperative Injection of Technetium-99m Sulfur Colloid for Sentinel Lymph Node Biopsy in Breast Cancer Patients: A Single Institution Experience (Full text)

Intraoperative Injection of Technetium-99m Sulfur Colloid for Sentinel Lymph Node Biopsy in Breast Cancer Patients: A Single Institution Experience Background. Most institutions require a patient undergoing sentinel lymph node biopsy to go through nuclear medicine prior to surgery to be injected with radioisotope. This study describes the long-term results using intraoperative injection of radioisotope. Methods. Since late 2002, all patients undergoing a sentinel lymph node biopsy at the Yale (...) -New Haven Breast Center underwent intraoperative injection of technetium-99m sulfur colloid. Endpoints included number of sentinel and nonsentinel lymph nodes obtained and number of positive sentinel and nonsentinel lymph nodes. Results. At least one sentinel lymph node was obtained in 2,333 out of 2,338 cases of sentinel node biopsy for an identification rate of 99.8%. The median number of sentinel nodes found was 2 and the mean was 2.33 (range: 1-15). There were 512 cases (21.9%) in which

2017 Surgery research and practice

79. Lymphoscintigraphy detecting alterations of upper limb lymphatic flow following early sentinel lymph node biopsy in breast cancer (Full text)

Lymphoscintigraphy detecting alterations of upper limb lymphatic flow following early sentinel lymph node biopsy in breast cancer To evaluate early variations in lymphatic circulation of the arm pre- and post-sentinel lymph node biopsy (SLNB) and conservative breast surgery by lymphoscintigraphy (LS).Between 2005 and 2012, 15 patients underwent LS before and after the SLNB (total=30 studies). The pre-SLNB study was considered the control. Early images within twenty minutes (dynamic and static (...) images) and delayed images within ninety minutes of arms and armpits were acquired using a gamma camera. The LS images before and after the SLNB of each patient were paired and compared to each other, evaluating the site of lymphatic flow (in the early phase) and identifying the number of lymph nodes (in the late phase). These dynamic images were subjected to additional quantitative analysis to assess the lymphatic flow rate using the slope assessed by the angular coefficient of the radioactivity

2017 Breast Cancer : Targets and Therapy

80. Primary ectopic breast cancer of the vulva, treated with local excision of the vulva and sentinel lymph node biopsy: a case report (Full text)

Primary ectopic breast cancer of the vulva, treated with local excision of the vulva and sentinel lymph node biopsy: a case report Primary breast cancer fairly infrequently occurs in ectopic breast tissue, and primary ectopic breast cancer of the vulva is particularly rare. Only 26 cases have been published in the English-language literature, and there has been no report of primary breast carcinoma of the vulva in Japan. We report a rare case of primary ectopic breast cancer of the vulva (...) that was treated with local excision of the vulva and sentinel lymph node biopsy (SLNB). The patient was a 72-year-old woman who had noticed a right vulvar tumor 10 years earlier. The tumor was excised by the Department of Plastic Surgery of our hospital. The histology of the vulvar tumor revealed an invasive ductal carcinoma of the breast, and immunohistochemical staining of the vulvar specimen showed the tumor cells to be 100% estrogen-receptor-positive and 100% progesterone-receptor-positive. All margins

2017 Surgical Case Reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>